PL – co-financed projects implemented


Increasing drug safety by implementing Celon Pharma S.A. in its own production innovative oral forms of three medicinal products used in the pharmacotherapy of cardiovascular diseases


FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases

Development of Innovative Therapeutic Solutions Using RNA Technology

Develop clinical candidates based on mRNA technology in 3 therapeutic areas (oncological, metabolic – AATD deficiency and viral – SARS-CoV2), as well as to develop and expand the competence of Celon Pharma S.A. in the area of pharmaceutical production in the area of mRNA


  CELONKO – “Development of modern biomarkers and development of an innovative FGFR kinases inhibitor”